Sphene Capital GmbH: Ikonisys SA | Rating: Buy
Original-Research: Ikonisys SA - von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Ikonisys SA
Unternehmen: Ikonisys SA
ISIN: FR00140048X2
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 06.02.2024
Kursziel: EUR 6,30 (bisher: EUR 4,50)
Kursziel auf Sicht von: 36 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA
Creating a leading player in cancer diagnostics
Only weeks after Ikonisys entered a strategic partnership with Biocare
Medical, the company made the next strategic step in business development
by announcing the takeover of Hospitex, an Italian-based cytology company
specialising in oncological diagnostics. According to the company, Hospitex
has developed a unique ecosystem around a technology called Nephelometric
Smart Technology (NST). Central to the ecosystem is CYTOfast Plus, which is
claimed to be the most advanced processing solution to produce filter-less,
standardized, single-layer liquid based cytology (LBC) diagnostic slides.
While competitor technologies were originally designed only for the
so-called Pap test, a screening test for cervical cancer, the patent
protected NST is the only certified technology for the entire cytology
universe and for all target organs, according to the company. We believe
that Hospitex could prove a perfect fit to extend Ikonisys’ value chain and
should significantly support the company's growth and profitability in the
years ahead. After adjusting our financial model to the acquisition and the
new number of shares, the intrinsic value derived from our three-stage DCF
entity model increases to EUR 6.30 from EUR 4.50 per share (base case
scenario). We reiterate our Buy rating.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/28825.pdf
Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553
peter-thilo.hasler@sphene-capital.de
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
